{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "585960b1",
   "metadata": {},
   "outputs": [],
   "source": [
    "from textwrap import wrap\n",
    "import pandas as pd\n",
    "import requests\n",
    "import json\n",
    "from pandas import json_normalize # tranform JSON file into a pandas dataframe\n",
    "import time\n",
    "import re\n",
    "\n",
    "pd.set_option('display.max_colwidth', 100)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "17e67ed0",
   "metadata": {},
   "outputs": [],
   "source": [
    "def build_url_from_query(query):\n",
    "    \n",
    "    query_tokenized = query.split()\n",
    "    \n",
    "    field_values = ['NCTId', 'BriefTitle', 'Condition', 'Phase', 'StudyType',\n",
    "                    'EnrollmentCount', 'StartDate', 'PrimaryCompletionDate', 'EligibilityCriteria', 'InterventionName', \n",
    "                    'ArmGroupInterventionName', 'ArmGroupDescription', 'InterventionArmGroupLabel', 'OutcomeMeasureType', 'OutcomeMeasureTitle',\n",
    "                    'OutcomeMeasureDescription', 'OutcomeMeasureTimeFrame', 'OutcomeMeasurementValue', 'OutcomeMeasureUnitOfMeasure']\n",
    "    \n",
    "    max_rank = 1000             # max # of items returned by the API query (max for the clinicaltrials.gov API is 1000)\n",
    "    \n",
    "    \n",
    "    url = 'https://clinicaltrials.gov/api/query/study_fields?expr='\n",
    "    \n",
    "    for i, word in enumerate(query_tokenized):              # build query URL by adding all search terms and field values to the query URL, following the appropriate format\n",
    "        if i == 0:\n",
    "            url = url + word\n",
    "        else:\n",
    "            url = url + '+' + word\n",
    "        \n",
    "    url = url + '&fields='\n",
    "    \n",
    "    for i, word in enumerate(field_values):\n",
    "        if i == 0:\n",
    "            url = url + word\n",
    "        else:\n",
    "            url = url + '%2C' + word\n",
    "    \n",
    "    url = url + '&min_rnk=1&max_rnk=' + str(max_rank) + '&fmt=json' \n",
    "    url = url.strip()\n",
    "    \n",
    "    # print('\\n\\nQuerying up to 1,000 trials from clinicaltrials.gov with the following url...\\n\\n'+url+'\\n\\n')\n",
    "    \n",
    "    return url"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "ad40ed71",
   "metadata": {},
   "outputs": [],
   "source": [
    "def clean_columns(df_master):\n",
    "    for col in df_master.columns[1:]:    \n",
    "        if not re.search('Outcome.*', col):\n",
    "            if len(df_master[col][0]) == 1:                                            \n",
    "                df_master[col] = df_master[col][0]\n",
    "            elif len(df_master[col][0]) > 1:\n",
    "                df_master[col] = ', '.join(df_master[col][0])\n",
    "            else:\n",
    "                df_master[col] = 'Unknown'    \n",
    "    return df_master"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "ee6bc704",
   "metadata": {},
   "outputs": [],
   "source": [
    "def map_measure_values(df_master):\n",
    "    num_of_outcomes = len(df_master['OutcomeMeasureType'][0])\n",
    "    temp_list = []\n",
    "    try:                            \n",
    "        measures_per_outcome = len(df_master['OutcomeMeasurementValue'][0])//len(df_master['OutcomeMeasureTitle'][0])\n",
    "    except:\n",
    "        measures_per_outcome = 1\n",
    "    \n",
    "    beginning = 0\n",
    "    increment = measures_per_outcome               # maps correct number of outcome measures reported in the study, as multiple performance values may pertain to each endpoint (i.e. value for each intervention arm + placebo)\n",
    "    try:\n",
    "        for i in range(num_of_outcomes):\n",
    "            try:\n",
    "                temp_list.append([df_master['OutcomeMeasurementValue'][0][beginning:beginning+increment]])\n",
    "                beginning += increment\n",
    "            except:\n",
    "                print('Errors!')\n",
    "        df_master['OutcomeMeasurementValue'] = temp_list\n",
    "    except:\n",
    "        print('Errors!')\n",
    "    \n",
    "    return df_master"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "ddeaf095",
   "metadata": {},
   "outputs": [],
   "source": [
    "def build_study_table(url):\n",
    "        \n",
    "    ## convert the clinicaltrials.gov JSON response to a pandas dataframe\n",
    "    \n",
    "    result = requests.get(url).json()\n",
    "    \n",
    "    result_list = [result for result in result['StudyFieldsResponse']['StudyFields'] if result['OutcomeMeasureType']]     #loop through the list and identify ONLY studies with outcome measures reported \n",
    "    df_master = json_normalize(result_list[0])      # initialize dataframe using JSON result\n",
    "\n",
    "    df_master = clean_columns(df_master)\n",
    "\n",
    "    try:\n",
    "        for study in result_list[1:]:        # concatenate each study to the dataframe to generate master dataframe\n",
    "            df = json_normalize(study)\n",
    "            df = clean_columns(df)\n",
    "            df_master = pd.concat([df_master, df], axis=0, ignore_index=True)\n",
    "    except:\n",
    "        print(\"There was an error!\")\n",
    "        \n",
    "    return df_master"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "ea84e562",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Enter search query: \n",
      "psoriasis\n",
      "Time to build url: 0.0 seconds\n",
      "https://clinicaltrials.gov/api/query/study_fields?expr=psoriasis&fields=NCTId%2CBriefTitle%2CCondition%2CPhase%2CStudyType%2CEnrollmentCount%2CStartDate%2CPrimaryCompletionDate%2CEligibilityCriteria%2CInterventionName%2CArmGroupInterventionName%2CArmGroupDescription%2CInterventionArmGroupLabel%2COutcomeMeasureType%2COutcomeMeasureTitle%2COutcomeMeasureDescription%2COutcomeMeasureTimeFrame%2COutcomeMeasurementValue%2COutcomeMeasureUnitOfMeasure&min_rnk=1&max_rnk=1000&fmt=json\n"
     ]
    }
   ],
   "source": [
    "query_term = input(\"Enter search query: \\n\")\n",
    "start_time = time.process_time()\n",
    "url = build_url_from_query(query_term)\n",
    "print(f\"Time to build url: {time.process_time()-start_time} seconds\")\n",
    "print(url)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "59c41e1c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Time to build table: 5.046875 seconds.\n"
     ]
    }
   ],
   "source": [
    "start_time = time.process_time()\n",
    "study_table = build_study_table(url)\n",
    "print(f\"Time to build table: {time.process_time()-start_time} seconds.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "57fabd1a",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>NCTId</th>\n",
       "      <th>BriefTitle</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Phase</th>\n",
       "      <th>StudyType</th>\n",
       "      <th>EnrollmentCount</th>\n",
       "      <th>StartDate</th>\n",
       "      <th>PrimaryCompletionDate</th>\n",
       "      <th>EligibilityCriteria</th>\n",
       "      <th>InterventionName</th>\n",
       "      <th>ArmGroupInterventionName</th>\n",
       "      <th>ArmGroupDescription</th>\n",
       "      <th>InterventionArmGroupLabel</th>\n",
       "      <th>OutcomeMeasureType</th>\n",
       "      <th>OutcomeMeasureTitle</th>\n",
       "      <th>OutcomeMeasureDescription</th>\n",
       "      <th>OutcomeMeasureTimeFrame</th>\n",
       "      <th>OutcomeMeasurementValue</th>\n",
       "      <th>OutcomeMeasureUnitOfMeasure</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT00800982</td>\n",
       "      <td>Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque ...</td>\n",
       "      <td>Psoriasis</td>\n",
       "      <td>Not Applicable</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>30</td>\n",
       "      <td>October 2008</td>\n",
       "      <td>January 2012</td>\n",
       "      <td>Inclusion Criteria:\\n\\nNonimmunocompromised males or females 18 years of age or older.\\nMust be ...</td>\n",
       "      <td>Narrow band (310-312 nm) ultraviolet light B phototherapy, etanercept</td>\n",
       "      <td>Drug: etanercept, Procedure: Narrow band (310-312 nm) ultraviolet light B phototherapy, Drug: et...</td>\n",
       "      <td>Subjects will only be treated with etanercept. This is given at the standard FDA approved dosage...</td>\n",
       "      <td>2 (Etanercept + nb-UVB), 1 (Etanercept only), 2 (Etanercept + nb-UVB)</td>\n",
       "      <td>[Primary]</td>\n",
       "      <td>[Psoriasis Area Severity Index. This Scale Ranges From 0-72, 0 Being no Disease, and 72 Being Mo...</td>\n",
       "      <td>[Psoriasis area severity index was used to determine the number of patients in each treatment ar...</td>\n",
       "      <td>[Weeks 12-24]</td>\n",
       "      <td>[6, 6]</td>\n",
       "      <td>[participants]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>5</td>\n",
       "      <td>NCT01916629</td>\n",
       "      <td>Photocil (Topical) for the Treatment of Psoriasis Vulgaris</td>\n",
       "      <td>Psoriasis</td>\n",
       "      <td>Not Applicable</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>12</td>\n",
       "      <td>August 2013</td>\n",
       "      <td>December 2014</td>\n",
       "      <td>Inclusion Criteria:\\n\\nDiagnosed with psoriasis vulgaris confirmed by a dermatologist\\nPsoriasis...</td>\n",
       "      <td>Photocil for Psoriasis, Placebo - Sunscreen (SPF 2)</td>\n",
       "      <td>Drug: Photocil for Psoriasis, Other: Placebo - Sunscreen (SPF 2)</td>\n",
       "      <td>Active Drug - Photocil for Psoriasis, Placebo - Sunscreen (SPF 2)</td>\n",
       "      <td>Photocil for Psoriasis, Placebo - Sunscreen (SPF 2)</td>\n",
       "      <td>[Primary]</td>\n",
       "      <td>[Percent Lesion Clearance]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[90 days]</td>\n",
       "      <td>[75.7, 8]</td>\n",
       "      <td>[Percent Clearance]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>8</td>\n",
       "      <td>NCT00115076</td>\n",
       "      <td>Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis</td>\n",
       "      <td>Psoriasis</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>31</td>\n",
       "      <td>August 4, 2003</td>\n",
       "      <td>May 18, 2009</td>\n",
       "      <td>Inclusion Criteria:\\n\\nSigned informed consent\\n\\nPlaque psoriasis covering &gt;10% of total BSA\\nD...</td>\n",
       "      <td>Efalizumab</td>\n",
       "      <td>Drug: Efalizumab</td>\n",
       "      <td>moderate to severe plaque psoriasis</td>\n",
       "      <td>psoriasis</td>\n",
       "      <td>[Primary, Secondary]</td>\n",
       "      <td>[Number of Participants With Clinical Improvement of Target Lesions, Assessment of Overall Clini...</td>\n",
       "      <td>[a single composite score based on quantitative measurement of epidermal acanthosis, qualitative...</td>\n",
       "      <td>[week 12, Day 0, day 14, day 42, day 84, Days 112, 140, and 168. PASI has been measured at those...</td>\n",
       "      <td>[18, 34.58, 12.94]</td>\n",
       "      <td>[Participants, score on a scale]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>11</td>\n",
       "      <td>NCT00195507</td>\n",
       "      <td>Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis</td>\n",
       "      <td>Psoriasis</td>\n",
       "      <td>Phase 4</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>720</td>\n",
       "      <td>December 2004</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Inclusion Criteria:\\n\\nStable, active plaque psoriasis\\nFailure to respond to the following syst...</td>\n",
       "      <td>Etanercept</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>[Primary, Secondary, Secondary, Secondary]</td>\n",
       "      <td>[Physician Global Assessment of Psoriasis (PGA) Score - Mean Value Over 54 Weeks, Patient Global...</td>\n",
       "      <td>[Physician Global Assessment of Psoriasis (PGA) is a 7-point scale used to assess severity of ps...</td>\n",
       "      <td>[54 weeks, 54 weeks, 54 weeks, 54 weeks]</td>\n",
       "      <td>[1.98, 2.51, 57.03, 40.92, 127, 168, 70, 80, 231, 198]</td>\n",
       "      <td>[units on scale, percentage improvement, days, participants]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>13</td>\n",
       "      <td>NCT01126619</td>\n",
       "      <td>A Study of Effectiveness and Safety of Tumor Necrosis Factor (TNF) Inhibitors in Patients With M...</td>\n",
       "      <td>Psoriasis</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Observational</td>\n",
       "      <td>103</td>\n",
       "      <td>May 2010</td>\n",
       "      <td>September 2011</td>\n",
       "      <td>Inclusion Criteria:\\n\\nMale or female patients ≥18 years old with moderate-to-severe psoriasis.\\...</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Participants with moderate to severe psoriasis who were prescribed an Anti Tumor Necrosis Factor...</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Primary, Secondary, Secondary]</td>\n",
       "      <td>[Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score, Dynamic Physici...</td>\n",
       "      <td>[The Psoriasis Area and Severity Index (PASI) score is a combination of the intensity of psorias...</td>\n",
       "      <td>[Baseline and Weeks 4, 8, 16 and 24, Baseline and Week 24, Baseline and Week 24, Baseline and We...</td>\n",
       "      <td>[48.65, 75.70, 87.85, 90.29, 1.51, 1.51, 0, 14, 0, 38, 0, 19, 1, 4, 35, 8, 27, 3, 23, 0, 53.13, ...</td>\n",
       "      <td>[Percent change, scores on a scale, scores on a scale, participants, percent change, percentage ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>352</th>\n",
       "      <td>987</td>\n",
       "      <td>NCT02407041</td>\n",
       "      <td>An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psori...</td>\n",
       "      <td>Psoriasis</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>5</td>\n",
       "      <td>September 2015</td>\n",
       "      <td>March 2018</td>\n",
       "      <td>Inclusion Criteria:\\n\\nEach subject must meet all of the following criteria to be enrolled in th...</td>\n",
       "      <td>GR-MD-02</td>\n",
       "      <td>Drug: GR-MD-02</td>\n",
       "      <td>active arm</td>\n",
       "      <td>GR-MD-02</td>\n",
       "      <td>[Primary]</td>\n",
       "      <td>[Number of Participants With PASI-75, or a 75% Improvement From Baseline in PASI Score]</td>\n",
       "      <td>[The primary endpoint will be the number of participants with PASI-75, or a 75% improvement from...</td>\n",
       "      <td>[6 months]</td>\n",
       "      <td>[1]</td>\n",
       "      <td>[Participants]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>353</th>\n",
       "      <td>989</td>\n",
       "      <td>NCT02533375</td>\n",
       "      <td>Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pus...</td>\n",
       "      <td>Generalized Pustular Psoriasis (GPP), Adalimumab, Japanese</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>10</td>\n",
       "      <td>September 28, 2015</td>\n",
       "      <td>September 15, 2016</td>\n",
       "      <td>Inclusion Criteria:\\n\\nDiagnosis of generalized pustular psoriasis\\nTotal skin score of at least...</td>\n",
       "      <td>Adalimumab</td>\n",
       "      <td>Drug: Adalimumab</td>\n",
       "      <td>80 mg at Week 0 by subcutaneous (SC) injection, followed by 40 mg every other week (eow) on and ...</td>\n",
       "      <td>Participants receiving adalimumab</td>\n",
       "      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n",
       "      <td>[Proportion of Participants Achieving Clinical Response at Week 16, Number of Participants Achie...</td>\n",
       "      <td>[Clinical Response was defined as reduction of the Generalized Pustular Psoriasis (GPP) total sk...</td>\n",
       "      <td>[Baseline and Week 16, Baseline, Week 2, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, Wee...</td>\n",
       "      <td>[7, 5, 6, 6, 5, 6, 6, 5, 0, 1, 0, 0, 0, 0, 0, 0, -2.9, -3.8, -3.2, -3.1, -4.6, -3.8, -5.5, -6.0,...</td>\n",
       "      <td>[Participants, participants, participants, units on a scale, Participants, units on a scale, per...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>354</th>\n",
       "      <td>991</td>\n",
       "      <td>NCT00704262</td>\n",
       "      <td>Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium M...</td>\n",
       "      <td>Psoriasis Vulgaris</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>33</td>\n",
       "      <td>May 2008</td>\n",
       "      <td>December 2009</td>\n",
       "      <td>Inclusion Criteria:\\n\\nClinical diagnosis of psoriasis vulgaris involving the face and the inter...</td>\n",
       "      <td>Calcipotriol plus hydrocortisone (LEO 80190)</td>\n",
       "      <td>Drug: Calcipotriol plus hydrocortisone (LEO 80190)</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Calcipotriol plus hydrocortisone (LEO 80190)</td>\n",
       "      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n",
       "      <td>[The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obt...</td>\n",
       "      <td>[The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) cha...</td>\n",
       "      <td>[At Week 4 (Day 28) and Week 8 (Day 56), From baseline to Week 4, Week 8, and end of treatment (...</td>\n",
       "      <td>[29, 1, 2.215, 0.002, -0.045, -0.033, 29, 1, 30, 0, 25.29, 25.93, 28.81, 28.82, 2.215, 0.018, -0...</td>\n",
       "      <td>[Participants, mmol/L, Participants, Participants, mcg/dL, mcg/dL, mmol/L, mmol/L, Participants,...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>355</th>\n",
       "      <td>993</td>\n",
       "      <td>NCT02748863</td>\n",
       "      <td>Study of Secukinumab With 2 mL Pre-filled Syringes</td>\n",
       "      <td>Psoriasis</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>214</td>\n",
       "      <td>December 12, 2016</td>\n",
       "      <td>August 8, 2017</td>\n",
       "      <td>Inclusion Criteria:\\n\\nSubjects eligible for inclusion in this study must fulfill all of the fol...</td>\n",
       "      <td>Placebo, Secukinumab 2 mL form, Secukinumab 1 mL form</td>\n",
       "      <td>Drug: Placebo, Drug: Secukinumab 2 mL form, Drug: Secukinumab 1 mL form</td>\n",
       "      <td>Placebo, provided in a 2 mL pre-filled syringe Placebo, provided in a 1 mL pre-filled syringe, S...</td>\n",
       "      <td>Placebo, Secukinumab 2 mL form, Secukinumab 1 mL form</td>\n",
       "      <td>[Primary, Secondary, Secondary, Secondary, Primary]</td>\n",
       "      <td>[Participants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of Treatm...</td>\n",
       "      <td>[Number of participants who achieved ≥ 75% reduction in PASI compared to baseline\\n\\nPASI is a c...</td>\n",
       "      <td>[12 weeks, 12 weeks, 12 weeks, up to week 52, 12 weeks]</td>\n",
       "      <td>[64, 1, 48, 1, 28, 26, 0, 1, 0, 0, 0, 0, 5, 5, 1, 0, 1, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0...</td>\n",
       "      <td>[participants, participants, participants, participants, participants]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>356</th>\n",
       "      <td>995</td>\n",
       "      <td>NCT01866592</td>\n",
       "      <td>Vascular Inflammation in Psoriasis - Extension Study</td>\n",
       "      <td>Psoriasis, Cardiovascular Disease</td>\n",
       "      <td>Phase 4</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>81</td>\n",
       "      <td>April 2013</td>\n",
       "      <td>August 8, 2016</td>\n",
       "      <td>Inclusion Criteria:\\n\\nMales and females 18 years of age and older.\\nSubject completed the VIP S...</td>\n",
       "      <td>Adalimumab</td>\n",
       "      <td>Drug: Adalimumab</td>\n",
       "      <td>Single-arm, open label extension trial to continue treatment with Humira (Adalimumab) subcutaneo...</td>\n",
       "      <td>Single-Arm, open-label extension trial</td>\n",
       "      <td>[Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Prima...</td>\n",
       "      <td>[Change in Vascular Inflammation, Change in Vascular Inflammation, Change in Cardiometabolic Bio...</td>\n",
       "      <td>[Change in total vascular inflammation of five aortic segments as assessed on FDG-PET/CT between...</td>\n",
       "      <td>[52 weeks (continuation group) or 64 weeks (crossover group), 52 weeks of adalimumab treatment, ...</td>\n",
       "      <td>[-3.8, 0.02, 3.164, -0.217, 22.537, -2.984, .118, -.074, .048, -.815, -.275, 1.054, -29.559, 1.1...</td>\n",
       "      <td>[percentage change, percentage change, mg/dL, no units, nmol/L, nmol/L, log(pg/mL), log(ug/mL), ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>357 rows × 20 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Rank        NCTId  \\\n",
       "0       3  NCT00800982   \n",
       "1       5  NCT01916629   \n",
       "2       8  NCT00115076   \n",
       "3      11  NCT00195507   \n",
       "4      13  NCT01126619   \n",
       "..    ...          ...   \n",
       "352   987  NCT02407041   \n",
       "353   989  NCT02533375   \n",
       "354   991  NCT00704262   \n",
       "355   993  NCT02748863   \n",
       "356   995  NCT01866592   \n",
       "\n",
       "                                                                                              BriefTitle  \\\n",
       "0    Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque ...   \n",
       "1                                             Photocil (Topical) for the Treatment of Psoriasis Vulgaris   \n",
       "2    Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis   \n",
       "3                                Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis   \n",
       "4    A Study of Effectiveness and Safety of Tumor Necrosis Factor (TNF) Inhibitors in Patients With M...   \n",
       "..                                                                                                   ...   \n",
       "352  An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psori...   \n",
       "353  Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pus...   \n",
       "354  Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium M...   \n",
       "355                                                   Study of Secukinumab With 2 mL Pre-filled Syringes   \n",
       "356                                                 Vascular Inflammation in Psoriasis - Extension Study   \n",
       "\n",
       "                                                      Condition  \\\n",
       "0                                                     Psoriasis   \n",
       "1                                                     Psoriasis   \n",
       "2                                                     Psoriasis   \n",
       "3                                                     Psoriasis   \n",
       "4                                                     Psoriasis   \n",
       "..                                                          ...   \n",
       "352                                                   Psoriasis   \n",
       "353  Generalized Pustular Psoriasis (GPP), Adalimumab, Japanese   \n",
       "354                                          Psoriasis Vulgaris   \n",
       "355                                                   Psoriasis   \n",
       "356                           Psoriasis, Cardiovascular Disease   \n",
       "\n",
       "              Phase       StudyType EnrollmentCount           StartDate  \\\n",
       "0    Not Applicable  Interventional              30        October 2008   \n",
       "1    Not Applicable  Interventional              12         August 2013   \n",
       "2           Phase 3  Interventional              31      August 4, 2003   \n",
       "3           Phase 4  Interventional             720       December 2004   \n",
       "4           Unknown   Observational             103            May 2010   \n",
       "..              ...             ...             ...                 ...   \n",
       "352         Phase 2  Interventional               5      September 2015   \n",
       "353         Phase 3  Interventional              10  September 28, 2015   \n",
       "354         Phase 2  Interventional              33            May 2008   \n",
       "355         Phase 3  Interventional             214   December 12, 2016   \n",
       "356         Phase 4  Interventional              81          April 2013   \n",
       "\n",
       "    PrimaryCompletionDate  \\\n",
       "0            January 2012   \n",
       "1           December 2014   \n",
       "2            May 18, 2009   \n",
       "3                 Unknown   \n",
       "4          September 2011   \n",
       "..                    ...   \n",
       "352            March 2018   \n",
       "353    September 15, 2016   \n",
       "354         December 2009   \n",
       "355        August 8, 2017   \n",
       "356        August 8, 2016   \n",
       "\n",
       "                                                                                     EligibilityCriteria  \\\n",
       "0    Inclusion Criteria:\\n\\nNonimmunocompromised males or females 18 years of age or older.\\nMust be ...   \n",
       "1    Inclusion Criteria:\\n\\nDiagnosed with psoriasis vulgaris confirmed by a dermatologist\\nPsoriasis...   \n",
       "2    Inclusion Criteria:\\n\\nSigned informed consent\\n\\nPlaque psoriasis covering >10% of total BSA\\nD...   \n",
       "3    Inclusion Criteria:\\n\\nStable, active plaque psoriasis\\nFailure to respond to the following syst...   \n",
       "4    Inclusion Criteria:\\n\\nMale or female patients ≥18 years old with moderate-to-severe psoriasis.\\...   \n",
       "..                                                                                                   ...   \n",
       "352  Inclusion Criteria:\\n\\nEach subject must meet all of the following criteria to be enrolled in th...   \n",
       "353  Inclusion Criteria:\\n\\nDiagnosis of generalized pustular psoriasis\\nTotal skin score of at least...   \n",
       "354  Inclusion Criteria:\\n\\nClinical diagnosis of psoriasis vulgaris involving the face and the inter...   \n",
       "355  Inclusion Criteria:\\n\\nSubjects eligible for inclusion in this study must fulfill all of the fol...   \n",
       "356  Inclusion Criteria:\\n\\nMales and females 18 years of age and older.\\nSubject completed the VIP S...   \n",
       "\n",
       "                                                          InterventionName  \\\n",
       "0    Narrow band (310-312 nm) ultraviolet light B phototherapy, etanercept   \n",
       "1                      Photocil for Psoriasis, Placebo - Sunscreen (SPF 2)   \n",
       "2                                                               Efalizumab   \n",
       "3                                                               Etanercept   \n",
       "4                                                                  Unknown   \n",
       "..                                                                     ...   \n",
       "352                                                               GR-MD-02   \n",
       "353                                                             Adalimumab   \n",
       "354                           Calcipotriol plus hydrocortisone (LEO 80190)   \n",
       "355                  Placebo, Secukinumab 2 mL form, Secukinumab 1 mL form   \n",
       "356                                                             Adalimumab   \n",
       "\n",
       "                                                                                ArmGroupInterventionName  \\\n",
       "0    Drug: etanercept, Procedure: Narrow band (310-312 nm) ultraviolet light B phototherapy, Drug: et...   \n",
       "1                                       Drug: Photocil for Psoriasis, Other: Placebo - Sunscreen (SPF 2)   \n",
       "2                                                                                       Drug: Efalizumab   \n",
       "3                                                                                                Unknown   \n",
       "4                                                                                                Unknown   \n",
       "..                                                                                                   ...   \n",
       "352                                                                                       Drug: GR-MD-02   \n",
       "353                                                                                     Drug: Adalimumab   \n",
       "354                                                   Drug: Calcipotriol plus hydrocortisone (LEO 80190)   \n",
       "355                              Drug: Placebo, Drug: Secukinumab 2 mL form, Drug: Secukinumab 1 mL form   \n",
       "356                                                                                     Drug: Adalimumab   \n",
       "\n",
       "                                                                                     ArmGroupDescription  \\\n",
       "0    Subjects will only be treated with etanercept. This is given at the standard FDA approved dosage...   \n",
       "1                                      Active Drug - Photocil for Psoriasis, Placebo - Sunscreen (SPF 2)   \n",
       "2                                                                    moderate to severe plaque psoriasis   \n",
       "3                                                                                                Unknown   \n",
       "4    Participants with moderate to severe psoriasis who were prescribed an Anti Tumor Necrosis Factor...   \n",
       "..                                                                                                   ...   \n",
       "352                                                                                           active arm   \n",
       "353  80 mg at Week 0 by subcutaneous (SC) injection, followed by 40 mg every other week (eow) on and ...   \n",
       "354                                                                                              Unknown   \n",
       "355  Placebo, provided in a 2 mL pre-filled syringe Placebo, provided in a 1 mL pre-filled syringe, S...   \n",
       "356  Single-arm, open label extension trial to continue treatment with Humira (Adalimumab) subcutaneo...   \n",
       "\n",
       "                                                 InterventionArmGroupLabel  \\\n",
       "0    2 (Etanercept + nb-UVB), 1 (Etanercept only), 2 (Etanercept + nb-UVB)   \n",
       "1                      Photocil for Psoriasis, Placebo - Sunscreen (SPF 2)   \n",
       "2                                                                psoriasis   \n",
       "3                                                                  Unknown   \n",
       "4                                                                  Unknown   \n",
       "..                                                                     ...   \n",
       "352                                                               GR-MD-02   \n",
       "353                                      Participants receiving adalimumab   \n",
       "354                           Calcipotriol plus hydrocortisone (LEO 80190)   \n",
       "355                  Placebo, Secukinumab 2 mL form, Secukinumab 1 mL form   \n",
       "356                                 Single-Arm, open-label extension trial   \n",
       "\n",
       "                                                                                      OutcomeMeasureType  \\\n",
       "0                                                                                              [Primary]   \n",
       "1                                                                                              [Primary]   \n",
       "2                                                                                   [Primary, Secondary]   \n",
       "3                                                             [Primary, Secondary, Secondary, Secondary]   \n",
       "4                   [Primary, Secondary, Secondary, Secondary, Secondary, Primary, Secondary, Secondary]   \n",
       "..                                                                                                   ...   \n",
       "352                                                                                            [Primary]   \n",
       "353  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n",
       "354  [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n",
       "355                                                  [Primary, Secondary, Secondary, Secondary, Primary]   \n",
       "356  [Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Prima...   \n",
       "\n",
       "                                                                                     OutcomeMeasureTitle  \\\n",
       "0    [Psoriasis Area Severity Index. This Scale Ranges From 0-72, 0 Being no Disease, and 72 Being Mo...   \n",
       "1                                                                             [Percent Lesion Clearance]   \n",
       "2    [Number of Participants With Clinical Improvement of Target Lesions, Assessment of Overall Clini...   \n",
       "3    [Physician Global Assessment of Psoriasis (PGA) Score - Mean Value Over 54 Weeks, Patient Global...   \n",
       "4    [Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score, Dynamic Physici...   \n",
       "..                                                                                                   ...   \n",
       "352              [Number of Participants With PASI-75, or a 75% Improvement From Baseline in PASI Score]   \n",
       "353  [Proportion of Participants Achieving Clinical Response at Week 16, Number of Participants Achie...   \n",
       "354  [The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obt...   \n",
       "355  [Participants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of Treatm...   \n",
       "356  [Change in Vascular Inflammation, Change in Vascular Inflammation, Change in Cardiometabolic Bio...   \n",
       "\n",
       "                                                                               OutcomeMeasureDescription  \\\n",
       "0    [Psoriasis area severity index was used to determine the number of patients in each treatment ar...   \n",
       "1                                                                                                     []   \n",
       "2    [a single composite score based on quantitative measurement of epidermal acanthosis, qualitative...   \n",
       "3    [Physician Global Assessment of Psoriasis (PGA) is a 7-point scale used to assess severity of ps...   \n",
       "4    [The Psoriasis Area and Severity Index (PASI) score is a combination of the intensity of psorias...   \n",
       "..                                                                                                   ...   \n",
       "352  [The primary endpoint will be the number of participants with PASI-75, or a 75% improvement from...   \n",
       "353  [Clinical Response was defined as reduction of the Generalized Pustular Psoriasis (GPP) total sk...   \n",
       "354  [The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) cha...   \n",
       "355  [Number of participants who achieved ≥ 75% reduction in PASI compared to baseline\\n\\nPASI is a c...   \n",
       "356  [Change in total vascular inflammation of five aortic segments as assessed on FDG-PET/CT between...   \n",
       "\n",
       "                                                                                 OutcomeMeasureTimeFrame  \\\n",
       "0                                                                                          [Weeks 12-24]   \n",
       "1                                                                                              [90 days]   \n",
       "2    [week 12, Day 0, day 14, day 42, day 84, Days 112, 140, and 168. PASI has been measured at those...   \n",
       "3                                                               [54 weeks, 54 weeks, 54 weeks, 54 weeks]   \n",
       "4    [Baseline and Weeks 4, 8, 16 and 24, Baseline and Week 24, Baseline and Week 24, Baseline and We...   \n",
       "..                                                                                                   ...   \n",
       "352                                                                                           [6 months]   \n",
       "353  [Baseline and Week 16, Baseline, Week 2, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, Wee...   \n",
       "354  [At Week 4 (Day 28) and Week 8 (Day 56), From baseline to Week 4, Week 8, and end of treatment (...   \n",
       "355                                              [12 weeks, 12 weeks, 12 weeks, up to week 52, 12 weeks]   \n",
       "356  [52 weeks (continuation group) or 64 weeks (crossover group), 52 weeks of adalimumab treatment, ...   \n",
       "\n",
       "                                                                                 OutcomeMeasurementValue  \\\n",
       "0                                                                                                 [6, 6]   \n",
       "1                                                                                              [75.7, 8]   \n",
       "2                                                                                     [18, 34.58, 12.94]   \n",
       "3                                                 [1.98, 2.51, 57.03, 40.92, 127, 168, 70, 80, 231, 198]   \n",
       "4    [48.65, 75.70, 87.85, 90.29, 1.51, 1.51, 0, 14, 0, 38, 0, 19, 1, 4, 35, 8, 27, 3, 23, 0, 53.13, ...   \n",
       "..                                                                                                   ...   \n",
       "352                                                                                                  [1]   \n",
       "353  [7, 5, 6, 6, 5, 6, 6, 5, 0, 1, 0, 0, 0, 0, 0, 0, -2.9, -3.8, -3.2, -3.1, -4.6, -3.8, -5.5, -6.0,...   \n",
       "354  [29, 1, 2.215, 0.002, -0.045, -0.033, 29, 1, 30, 0, 25.29, 25.93, 28.81, 28.82, 2.215, 0.018, -0...   \n",
       "355  [64, 1, 48, 1, 28, 26, 0, 1, 0, 0, 0, 0, 5, 5, 1, 0, 1, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0...   \n",
       "356  [-3.8, 0.02, 3.164, -0.217, 22.537, -2.984, .118, -.074, .048, -.815, -.275, 1.054, -29.559, 1.1...   \n",
       "\n",
       "                                                                             OutcomeMeasureUnitOfMeasure  \n",
       "0                                                                                         [participants]  \n",
       "1                                                                                    [Percent Clearance]  \n",
       "2                                                                       [Participants, score on a scale]  \n",
       "3                                           [units on scale, percentage improvement, days, participants]  \n",
       "4    [Percent change, scores on a scale, scores on a scale, participants, percent change, percentage ...  \n",
       "..                                                                                                   ...  \n",
       "352                                                                                       [Participants]  \n",
       "353  [Participants, participants, participants, units on a scale, Participants, units on a scale, per...  \n",
       "354  [Participants, mmol/L, Participants, Participants, mcg/dL, mcg/dL, mmol/L, mmol/L, Participants,...  \n",
       "355                               [participants, participants, participants, participants, participants]  \n",
       "356  [percentage change, percentage change, mg/dL, no units, nmol/L, nmol/L, log(pg/mL), log(ug/mL), ...  \n",
       "\n",
       "[357 rows x 20 columns]"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "study_table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "58ff2f8d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Errors!\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>NCTId</th>\n",
       "      <th>BriefTitle</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Phase</th>\n",
       "      <th>StudyType</th>\n",
       "      <th>EnrollmentCount</th>\n",
       "      <th>StartDate</th>\n",
       "      <th>PrimaryCompletionDate</th>\n",
       "      <th>EligibilityCriteria</th>\n",
       "      <th>InterventionName</th>\n",
       "      <th>ArmGroupInterventionName</th>\n",
       "      <th>ArmGroupDescription</th>\n",
       "      <th>InterventionArmGroupLabel</th>\n",
       "      <th>OutcomeMeasureType</th>\n",
       "      <th>OutcomeMeasureTitle</th>\n",
       "      <th>OutcomeMeasureDescription</th>\n",
       "      <th>OutcomeMeasureTimeFrame</th>\n",
       "      <th>OutcomeMeasurementValue</th>\n",
       "      <th>OutcomeMeasureUnitOfMeasure</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT00800982</td>\n",
       "      <td>Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque ...</td>\n",
       "      <td>Psoriasis</td>\n",
       "      <td>Not Applicable</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>30</td>\n",
       "      <td>October 2008</td>\n",
       "      <td>January 2012</td>\n",
       "      <td>Inclusion Criteria:\\n\\nNonimmunocompromised males or females 18 years of age or older.\\nMust be ...</td>\n",
       "      <td>Narrow band (310-312 nm) ultraviolet light B phototherapy, etanercept</td>\n",
       "      <td>Drug: etanercept, Procedure: Narrow band (310-312 nm) ultraviolet light B phototherapy, Drug: et...</td>\n",
       "      <td>Subjects will only be treated with etanercept. This is given at the standard FDA approved dosage...</td>\n",
       "      <td>2 (Etanercept + nb-UVB), 1 (Etanercept only), 2 (Etanercept + nb-UVB)</td>\n",
       "      <td>Primary</td>\n",
       "      <td>Psoriasis Area Severity Index. This Scale Ranges From 0-72, 0 Being no Disease, and 72 Being Mos...</td>\n",
       "      <td>Psoriasis area severity index was used to determine the number of patients in each treatment arm...</td>\n",
       "      <td>Weeks 12-24</td>\n",
       "      <td>6, 6</td>\n",
       "      <td>participants</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Rank        NCTId  \\\n",
       "0     3  NCT00800982   \n",
       "\n",
       "                                                                                            BriefTitle  \\\n",
       "0  Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque ...   \n",
       "\n",
       "   Condition           Phase       StudyType EnrollmentCount     StartDate  \\\n",
       "0  Psoriasis  Not Applicable  Interventional              30  October 2008   \n",
       "\n",
       "  PrimaryCompletionDate  \\\n",
       "0          January 2012   \n",
       "\n",
       "                                                                                   EligibilityCriteria  \\\n",
       "0  Inclusion Criteria:\\n\\nNonimmunocompromised males or females 18 years of age or older.\\nMust be ...   \n",
       "\n",
       "                                                        InterventionName  \\\n",
       "0  Narrow band (310-312 nm) ultraviolet light B phototherapy, etanercept   \n",
       "\n",
       "                                                                              ArmGroupInterventionName  \\\n",
       "0  Drug: etanercept, Procedure: Narrow band (310-312 nm) ultraviolet light B phototherapy, Drug: et...   \n",
       "\n",
       "                                                                                   ArmGroupDescription  \\\n",
       "0  Subjects will only be treated with etanercept. This is given at the standard FDA approved dosage...   \n",
       "\n",
       "                                               InterventionArmGroupLabel  \\\n",
       "0  2 (Etanercept + nb-UVB), 1 (Etanercept only), 2 (Etanercept + nb-UVB)   \n",
       "\n",
       "  OutcomeMeasureType  \\\n",
       "0            Primary   \n",
       "\n",
       "                                                                                   OutcomeMeasureTitle  \\\n",
       "0  Psoriasis Area Severity Index. This Scale Ranges From 0-72, 0 Being no Disease, and 72 Being Mos...   \n",
       "\n",
       "                                                                             OutcomeMeasureDescription  \\\n",
       "0  Psoriasis area severity index was used to determine the number of patients in each treatment arm...   \n",
       "\n",
       "  OutcomeMeasureTimeFrame OutcomeMeasurementValue OutcomeMeasureUnitOfMeasure  \n",
       "0             Weeks 12-24                    6, 6                participants  "
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "map_measure_values(study_table)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
